Iovance Biotherapeutics (NASDAQ:IOVA) & Artiva Biotherapeutics (NASDAQ:ARTV) Critical Comparison

Artiva Biotherapeutics (NASDAQ:ARTV) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Profitability

This table compares Artiva Biotherapeutics and Iovance Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	N/A	N/A
Iovance Biotherapeutics	-1,343.27%	-65.04%	-50.79%

Valuation & Earnings

This table compares Artiva Biotherapeutics and Iovance Biotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
Iovance Biotherapeutics	$1.19 million	2,690.13	-$444.04 million	($1.67)	-6.85

Artiva Biotherapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics.

Analyst Recommendations

This is a summary of current ratings and target prices for Artiva Biotherapeutics and Iovance Biotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	0	0	5	0	3.00
Iovance Biotherapeutics	0	1	8	0	2.89

Artiva Biotherapeutics presently has a consensus target price of $21.25, suggesting a potential upside of 89.90%. Iovance Biotherapeutics has a consensus target price of $22.33, suggesting a potential upside of 95.22%. Given Iovance Biotherapeutics’ higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Artiva Biotherapeutics.

Insider and Institutional Ownership

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 12.1% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Iovance Biotherapeutics beats Artiva Biotherapeutics on 5 of the 9 factors compared between the two stocks.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.